ADMA Q2 2018 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+37.0% YoY

Gross Profit

-$5M-107.1% margin

Operating Income

-$13M-288.1% margin

Net Income

-$15M-316.7% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+15.2%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$535,391

Balance Sheet

Total Assets

$118M

Total Liabilities

$66M

Stockholders' Equity

$52M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$3M	+37.0%
Gross Profit	-$5M	-$934,618	-433.8%
Operating Income	-$13M	-$8M	-59.7%
Net Income	-$15M	-$9M	-63.2%